Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemoradiotherapy followed by TEM for distal rectal cancer
2010-019233-97Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Apr 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine in rectal cancer, sponsored by Radboud University Medical Center. Primary endpoint: Minimal residual disease rate (ypT0-1) after neoadjuvant therapy and TEM. Started Apr 2010; status: completed.
02
Drugs
capecitabine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on 2010-019233-97.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019233-97.